6-(1h-Indazol-5-yl)-4-(4-pyridinyl)quinoline | 1086060-00-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-(1h-Indazol-5-yl)-4-(4-pyridinyl)quinoline
• 英文别名: 6-(1H-indazol-5-yl)-4-pyridin-4-ylquinoline
• CAS: 1086060-00-5
• 化学式: C₂₁H₁₄N₄
• 分子量: 322.369
• InChiKey: DTSBCBAYOGVOSD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  25
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  6-溴-4-氯喹啉 在 盐酸 、 四(三苯基膦)钯 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 potassium acetate 、 potassium carbonate 、 联硼酸频那醇酯 作用下， 以 1,4-二氧六环 、 乙醚 、 水 为溶剂， 生成 6-(1h-Indazol-5-yl)-4-(4-pyridinyl)quinoline
  参考文献：
  名称：

  Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin

  摘要：

  Phosphomositide 3-kinase alpha (PI3K alpha) is a critical regulator of cell growth and transformation, and its signaling pathway is the most commonly mutated pathway in human cancers The mammalian target of rapamycin (mTOR), a class IV PI3K protein kinase, is also a central regulator of cell growth, and mTOR inhibitors are believed to augment the antiproliferative efficacy of PI3K/AKT pathway inhibition 2,4-Difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide (GSK2126458, 1) has been identified as a highly potent, orally bioavailable inhibitor of PI3K alpha and mTOR with in vivo activity in both pharrnacodynamic and tumor growth efficacy models Compound 1 is currently being evaluated in human clinical trials for the treatment of cancer.

  DOI：

  10.1021/ml900028r

文献信息

• QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS
  申请人：Adams Nicholas D.

  公开号：US20080300239A1

  公开（公告）日：2008-12-04

  Invented is a method of inhibiting the activity/function of PI3 kinases using quinoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoline derivatives.

  本发明涉及使用喹啉衍生物抑制PI3激酶的活性/功能的方法。本发明还涉及使用喹啉衍生物治疗自身免疫性疾病、炎症性疾病、心血管疾病、神经退行性疾病、过敏、哮喘、胰腺炎、多器官衰竭、肾脏疾病、血小板聚集、癌症、精子运动性、移植排斥、移植物排斥和肺损伤的方法。
• QUINOLINE DERIVATIVES AS P13 KINASE INHIBITORS
  申请人：Adams Nicholas D.

  公开号：US20100152112A1

  公开（公告）日：2010-06-17

  Invented is a method of inhibiting the activity/function of PI3 kinases using quinoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoline derivatives.

  发明了一种使用喹啉衍生物抑制PI3激酶活性/功能的方法。同时，还发明了一种使用喹啉衍生物治疗自身免疫疾病、炎症性疾病、心血管疾病、神经退行性疾病、过敏、哮喘、胰腺炎、多器官功能衰竭、肾脏疾病、血小板聚集、癌症、精子运动性、移植排斥、移植物排斥和肺部损伤的方法。
• Quinoline derivatives as PI3 kinase inhibitors
  申请人：Glaxosmithkline LLC

  公开号：EP2596793A1

  公开（公告）日：2013-05-29

  Invented is a method of inhibiting the activity/function of P13 kinases using quinoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoline derivatives.

  本发明是一种使用喹啉衍生物抑制 P13 激酶活性/功能的方法。还发明了一种通过服用喹啉衍生物治疗一种或多种疾病状态的方法，这些疾病状态选自：自身免疫性疾病、炎症性疾病、心血管疾病、神经退行性疾病、过敏、哮喘、胰腺炎、多器官功能衰竭、肾脏疾病、血小板聚集、癌症、精子活力、移植排斥、移植物排斥和肺损伤。
• US8138347B2
  申请人：——

  公开号：US8138347B2

  公开（公告）日：2012-03-20
• US8404837B2
  申请人：——

  公开号：US8404837B2

  公开（公告）日：2013-03-26